An Individualized Approach to PAH Therapy Based on Clinical Data, Goal-Directed Therapy, and Risk Stratification

Pulmonary arterial hypertension requires risk stratification to develop goal-directed treatment plans, including combination therapy targeting multiple pathways.
Category
- Cardiology
- Comorbidity
- Education
- Integrated Care
- Medical Conditions
- Pulmonary Disease
Format
- Video
- Self-study / Enduring
Credits
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Translating Clinical Trial Data into Real-World Practice: Examining CKD Screening and Three Patient Case Profiles

Regular screening of UACR and adding finerenone to SGLT2 inhibitors can greatly impact T2D at risk for CKD. Join faculty as they discuss three patient cases.
Category
- Renal Disease
- Adherence
- Cardiology
- Comorbidity
- Diagnostic Tools
- Education
- Medical Conditions
- Primary Care
- Side Effects
- Weight
Format
- Video
- Self-study / Enduring
Credits
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Part 1: A Review of Schizophrenia

Schizophrenia affects 1% of the world’s population largely during a patient’s most productive years. Multiple treatments are available, however many gaps to recovery exist. Learn from experts diagnostic criteria for and defining recovery in schizophrenia.
Category
- Schizophrenia/ Schizoaffective Disorders
Format
- Video
- Self-study / Enduring
Credits
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
Part 2: Chasing Cognitive and Negative Symptoms: Unmet Treatment Needs of Patients with Schizophrenia

Negative symptoms contribute to poor functional outcomes in schizophrenia. Evaluating different symptom domains and understanding the disorder’s reward circuitry can help with intervention and patients’ leading more fulfilling lives.
Category
- Schizophrenia/ Schizoaffective Disorders
Format
- Video
- Self-study / Enduring
Credits
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
Part 3: Impact of Side Effects on Adherence to Schizophrenia Treatment

Side effects from medication have the greatest impact on adherence for patients with Schizophrenia. They lower quality of life, daily functioning, and satisfaction.
Category
- Schizophrenia/ Schizoaffective Disorders
Format
- Video
- Self-study / Enduring
Credits
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
Patient-Specific Considerations, the GABA Pathway, and New Clinical Trial Data on Neuroactive Steroids in MDD and PPD

Studies evaluating neuroactive steroid GABA-A receptor positive allosteric modulators demonstrate promising results for the treatment of MDD and PPD.
Category
- Depression
- Major Depressive Disorder
- Women’s Mental Health
Format
- Journal
- Self-study / Enduring
Credits
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation
Diagnosing and Treating Alzheimer Disease During the Early Stage

Many new therapies for early-stage AD have made their way onto the scene that can delay onset of the disease and/or slow down progression. Find out the how, what, when to better treat your patients with AD from specialists in the field.
Category
- Alzheimer Disease
Format
- Journal
- Self-study / Enduring
Credits
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Comparing LAI and Oral Antipsychotic Options: Expert Discussions with Schizophrenia Case Reports

LAI antipsychotics are often initiated late in adults with schizophrenia, despite evidence supporting early use. Experts discuss the barriers to initiating LAI treatment, as well as adherence, efficacy and safety data.
Category
- Schizophrenia/ Schizoaffective Disorders
Format
- Video
- Self-study / Enduring
Credits
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Agitation in Bipolar Disorder and Schizophrenia: Emergency Department Considerations

In treating agitation in bipolar disorder/schizophrenia in the emergency department, consider efficacy and safety of therapies as well as the safety of patient and staff.
Category
- Bipolar Disorder
- Schizophrenia/ Schizoaffective Disorders
Format
- Video
- Self-study / Enduring
Credits
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
Cognitive Impairment in Huntington Disease

An updated review of pathophysiology, emerging treatments, and supportive care strategies in the cognitive dimension of Huntington disease.
Category
- Movement Disorders
- Neurology
Format
- Video
- Self-study / Enduring
Credits
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation